Pelthos Therapeutics Inc. (PTHS) fundamentals score
Pelthos Therapeutics Inc. is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (“FDA”) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMI TM , XEPI , and XEGLYZE .
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NYSE
Overall: 3.1 out of 10, Unhealthy fundamentals
- Growth: 1.5/10
- Profitability: 3.2/10
- Financial health: 4.4/10
- Earnings quality: 5.6/10
- Valuation: 1.5/10
Scores are calculated from Pelthos Therapeutics Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10